Dr Reddy’s Laboratories Ltd said on February 25 that the American drugs regulator finished inspecting its API manufacturing facility in Hyderabad. USFDA classified the inspection as Voluntary Action Indicated (VAI) and marked it as “closed”, giving the facility a chance to address the identified issues without immediate action.
